TY - JOUR
T1 - Retinal transcriptome profiling at transcription start sites
T2 - A cap analysis of gene expression early after axonal injury
AU - Yasuda, Masayuki
AU - Tanaka, Yuji
AU - Nishiguchi, Koji M.
AU - Ryu, Morin
AU - Tsuda, Satoru
AU - Maruyama, Kazuichi
AU - Nakazawa, Toru
N1 - Funding Information:
(http://www.senju.co.jp/), and NIDEK Co., Ltd. (http://www.nidek.co.jp/index-j. html). This study received additional support from the Great East Japan Earthquake Reconstruction Support Project of the Genome Network Analysis Support Facility (GeNAS) of the RIKEN Center for Life Science Technologies and Illumina K.K. We thank the GeNAS for preparing the CAGE library and performing the sequencing. We thank the Cell Innovation Program (National Institute of Genetics, Japan) for providing the data analysis platform and thank Mr. Norikazu Monma for technical advice regarding the usage of the platform. We also thank Ms. Junko Sato for technical assistance and thank Mr. Tim Hilts for editing this manuscript.
Funding Information:
This work was supported in part by JSPS KAKENHI Grants-in-Aid for Scientific Research B (T.N. 26293372) and for Challenging Exploratory Research (Y.T. 26670263 and T.N. 26670751). This study was also supported by the JST Center for Revitalization Promotion (Y.T. and T.N.), Senju Pharmaceutical Co., Ltd.
Publisher Copyright:
© 2014 Yasuda et al.. licensee BioMed Central Ltd.
PY - 2014/11/18
Y1 - 2014/11/18
N2 - Background: Glaucoma is characterized by progressive loss of the visual field and death of retinal ganglion cells (RGCs), a process that is mediated, in part, by axonal injury. However, the molecular pathomechanisms linking RGC death and axonal injury remain largely unknown. Here, we examined these mechanisms with a cap analysis of gene expression (CAGE), which allows the comprehensive quantification of transcription initiation across the entire genome. We aimed to identify changes in gene expression patterns and to predict the resulting alterations in the protein network in the early phases of axonal injury in mice. Results: We performed optic nerve crush (ONC) in mice to model axonal injury. Two days after ONC, the retinas were isolated, RNA was extracted, and a CAGE library was constructed and sequenced. CAGE data for ONC eyes and sham-treated eyes was compared, revealing 180 differentially expressed genes. Among them, the Bcat1 gene, involved in the catabolism of branched-chain amino acid transaminase, showed the largest change in expression (log2 fold-change = 6.70). In some differentially expressed genes, alternative transcription start sites were observed in the ONC eyes, highlighting the dynamism of transcription initiation in a state of disease. In silico pathway analysis predicted that ATF4 was the most significant upstream regulator orchestrating pathological processes after ONC. Its downstream candidate targets included Ddit3, which is known to induce cell death under endoplasmic reticulum stress. In addition, a regulatory network comprising IFNG, P38 MAPK, and TP53 was predicted to be involved in the induction of cell death. Conclusion: Through CAGE, we have identified differentially expressed genes that may account for the link between axonal injury and RGC death. Furthermore, an in silico pathway analysis provided a global view of alterations in the networks of key regulators of biological pathways that presumably take place in ONC. We thus believe that our study serves as a valuable resource to understand the molecular processes that define axonal injury-driven RGC death.
AB - Background: Glaucoma is characterized by progressive loss of the visual field and death of retinal ganglion cells (RGCs), a process that is mediated, in part, by axonal injury. However, the molecular pathomechanisms linking RGC death and axonal injury remain largely unknown. Here, we examined these mechanisms with a cap analysis of gene expression (CAGE), which allows the comprehensive quantification of transcription initiation across the entire genome. We aimed to identify changes in gene expression patterns and to predict the resulting alterations in the protein network in the early phases of axonal injury in mice. Results: We performed optic nerve crush (ONC) in mice to model axonal injury. Two days after ONC, the retinas were isolated, RNA was extracted, and a CAGE library was constructed and sequenced. CAGE data for ONC eyes and sham-treated eyes was compared, revealing 180 differentially expressed genes. Among them, the Bcat1 gene, involved in the catabolism of branched-chain amino acid transaminase, showed the largest change in expression (log2 fold-change = 6.70). In some differentially expressed genes, alternative transcription start sites were observed in the ONC eyes, highlighting the dynamism of transcription initiation in a state of disease. In silico pathway analysis predicted that ATF4 was the most significant upstream regulator orchestrating pathological processes after ONC. Its downstream candidate targets included Ddit3, which is known to induce cell death under endoplasmic reticulum stress. In addition, a regulatory network comprising IFNG, P38 MAPK, and TP53 was predicted to be involved in the induction of cell death. Conclusion: Through CAGE, we have identified differentially expressed genes that may account for the link between axonal injury and RGC death. Furthermore, an in silico pathway analysis provided a global view of alterations in the networks of key regulators of biological pathways that presumably take place in ONC. We thus believe that our study serves as a valuable resource to understand the molecular processes that define axonal injury-driven RGC death.
KW - Axonal injury
KW - CAGE
KW - Cap analysis of gene expression
KW - Optic nerve crush
KW - RGC
KW - Retinal ganglion cells
KW - Transcription start sites
KW - Transcriptome
UR - http://www.scopus.com/inward/record.url?scp=84924285405&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924285405&partnerID=8YFLogxK
U2 - 10.1186/1471-2164-15-982
DO - 10.1186/1471-2164-15-982
M3 - Article
C2 - 25407019
AN - SCOPUS:84924285405
SN - 1471-2164
VL - 15
JO - BMC Genomics
JF - BMC Genomics
IS - 1
M1 - 982
ER -